FutureChem Co Ltd
KOSDAQ:220100
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7 800
30 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
FutureChem Co Ltd
Accounts Receivables
FutureChem Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Accounts Receivables
₩3.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Accounts Receivables
₩1T
|
CAGR 3-Years
40%
|
CAGR 5-Years
62%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Accounts Receivables
₩5.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Accounts Receivables
₩121.3B
|
CAGR 3-Years
39%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Accounts Receivables
₩15.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
124%
|
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Accounts Receivables
₩1.8B
|
CAGR 3-Years
286%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
FutureChem Co Ltd
Glance View
FutureChem Co., Ltd. engages in the manufacture of medical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2015-08-13. Co.,Ltd is a Korea-based company principally engaged in the manufacture and distribution of radiopharmaceuticals. The firm manufactures radiopharmaceuticals including radiopharmaceuticals for diagnosis of various cancers such as lung cancer and for the early diagnosis of Parkinson's disease and Alzheimer's disease. The firm also produces medical automation modules such as cubes and disposable goods including disposable cassettes, reagent kits, radio-caps and kryptofix kits; productions of photon emission tomography (PET) and single photon emission computed tomography (SPECT) precursors for radiopharmaceuticals and other chemicals such as metal chelating agents, fluorescence probes, peptides.
See Also
What is FutureChem Co Ltd's Accounts Receivables?
Accounts Receivables
3.1B
KRW
Based on the financial report for Jun 30, 2024, FutureChem Co Ltd's Accounts Receivables amounts to 3.1B KRW.
What is FutureChem Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
8%
Over the last year, the Accounts Receivables growth was -3%. The average annual Accounts Receivables growth rates for FutureChem Co Ltd have been 7% over the past three years , 8% over the past five years .
You don't have any saved screeners yet
